Looking to battle leukemia: Syros Pharmaceuticals rates IPO at $12.50, here the range
6/30/16
| Syros Pharmaceuticals, whom is producing gene expression treatments based regard non-coding DNA research, improved $fifty thousand by supplying 4 thousand shares at $12.50, here the scale of $14 to $16. Syros Pharmaceuticals strategies to checklist regard the Nasdaq under the symbol SYRS. Cowen & Business that time Piper Jaffray acted as direct supervisors regard the deal. |
